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There has been considerable interest in DNA topoisomerases over the last decade, as they
have been shown to be one of the major cellular targets in anticancer drug development.
Previously we synthesized some benzothiazole derivatives and corresponding benzothiazoli-
um forms, and tested their DNA inhibitory activity to develop novel antitumor agents.
Among the 12 prepared compounds, compound BM3 (3-aminobenzothiazole-3-ium
4-methylbenzene sulfonate) exhibited extreme topoisomerase II inhibitory activity com-
pared with the reference drug etoposide. We also tried to determine the DNA and enzyme
binding abilities of BM3 and found that BM3 acted on topoisomerase II first at low doses,
while it had also showed DNA minor groove binding properties at higher doses. In this
study the interactions between DNA topoisomerase II and the compounds were examined
in detail by molecular modelling studies such as molecular docking and pharmacophore
analysis performed using Discovery Studio 3.5. As a result, it was found that benzothiazo-
lium compounds exhibited a totally different mechanism than benzothiazoles by binding to
the different amino acids at the active site of the protein molecule. 3-Aminobenzothiazoli-
ums are worthy of carrying onto anticancer studies; BM3 especially would be a good
anticancer candidate for preclinical studies.
Keywords: anticancer; benzothiazole; benzothiazolium; molecular docking; pharmacophore
analysis; topoisomerase II
1. Introduction
There are many benefits for the stable storage of genetic information in the double-helical
structure of DNA. It is protected from chemical damage by sequestering information-rich
nucleotides, while complementarity among the sister strands allows mistakes, lesions and dis-
continuities in the genome to be addressed and repaired. However, the intertwined structure
of duplex DNA is not without drawbacks. Because the two strands of deoxyribonucleic acid
are wound around one another, processes that require strand separation, such as replication or
transcription, lead naturally to DNA overwinding and strand entanglement which can pose
serious challenges to the cell [1–3]. They interfere with gene expression, DNA duplication and
chromosome segregation, and cells depend on DNA supercoiling as a means of compacting
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the genome and promoting DNA unwinding at replication origins and promoter regions at the
same time [2,3]. Thus, the cell strives to preserve the information content of the genome and
invests considerable energy in maintaining the topology of its chromosomes in an appropriate
topological state.
DNA topoisomerases are the ubiquitous enzymes in key cellular processes such as rep-
lication, transcription, recombination and repair, and chromatin assembly by solving these
topological problems of genomic DNA [4–10]. DNA topoisomerases are divided into two
classes depending on the number of broken strands (type I cuts one strand, type II cuts
both strands) of DNA by the enzymes in one reaction circle. In recent years, topoisome-
rases have become popular targets for cancer chemotherapy treatments. It is thought that
topoisomerase inhibitors block the ligation step of the cell cycle, generating single- and
double-stranded breaks that harm the integrity of the genome. Introduction of these breaks
subsequently leads to apoptosis and cell death. Lack of topoisomerase in the cell is fatal.
In light of this fact, DNA topoisomerases have been targeted for killing cancer cells or
pathogenic bacteria in the clinic. The purpose of this study is to identify a new type of
anticancer drug candidates.
Indeed, there are commercially available anticancer drugs that possess DNA topoisomer-
ase inhibitory activity such as doxorubicin, etoposide and camptothecin [11–14]. Our group
has been working for many years on the synthesis of some new heterocyclic compounds that
were potentially DNA topoisomerase I and II inhibitors, and molecular modelling studies of
these compounds [15–21]. So far some of the compounds exhibited significant topoisomerase
II inhibitory activity with IC50 values differing from 11.4 and 46.8 μM compared with the
standard drug etoposide [15,18]. Recently, we also reported results obtained through a DNA
topoisomerase relaxation assay indicated 2-substituted benzyl or phenyl benzothiazole deriva-
tives and corresponding 3-aminobenzothiazole-3-ium 4-methylbenzene sulfonates were strong
topoisomerase II inhibitors (Table 1).
In this research, the DNA topoisomerase II inhibitory activity of 3-amino-2-(2-bromoben-
zyl)-1,3-benzothiazole-3-ium 4-methylbenzene sulfonate (BM3) was the most effective DNA
topoisomerase II inhibitor with the lowest IC50 value of 39 nM, which could be considered
Table 1. IC50 values of benzothiazole and 3-amino-benzothiazolium derivatives for catalytic inhibitory















Compound X R Topo II IC50 Compound X R Topo II IC50
M2 CH2 2-F 1.06 mM BM6 CH2 2-F 1.78 mM
M6 CH2 4-CH3 72.93 μM BM1 CH2 4-CH3 6.87 mM
M7 CH2 4-Cl 107.10 μM BM7 CH2 4-Cl 6.20 mM
M9 CH2 4-Br 8.10 μM BM2 CH2 4-Br 8.46 mM
M10 CH2 2-Br 788.00 μM BM3 CH2 2-Br 39.40 nM
†
M15 – 2-Br 6.68 mM BM4 – 2-Br 1.26 mM
†Most effective compound.
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as an extremely strong activity compared with etoposide. According to the mechanistic
studies, BM3 was neither a DNA intercalator nor a topoisomerase poison; it was only a DNA
minor groove-binding agent [21]. BM3 initially bound to the DNA topoisomerase II enzyme
and its mechanisms of action might be directly interaction with the enzyme. It is reported that
there is a clear evidence for a covalent 5′ link between DNA and the active site tyrosine
(Tyr782) resident in topoisomerase II’s winged helix domain (WHD). Topoisomerase II
undergoes substantial conformational changes on binding substrate. Structures of apo
Saccharomyces cerevisiae topoisomerase II have shown that the two dimer-related WHDs and
their resident active site tyrosines are separated by 25–30 Å (Figure 1A). In the presence of
DNA, however, these elements move towards each other, forming a nearly contiguous
interaction surface across both protomers [22,23].
Hence, BM3 could be a good candidate as a new anticancer agent. We attempted to sup-
port the experimental results with theoretical findings by working with molecular modeling
techniques such as docking and pharmacophore generation using Accelrys Discovery Studio
(DS) 3.5 software [24]. These may direct us to find novel and more potent topoisomerase II
inhibitors.
In the drug design area, quantitative structure–activity relationship (QSAR) method is an
area of research pioneered by Hansch and Leo [25] and Hansch and Fujita [26]. The QSAR
method assumes that differences in the measured structural or physical properties account
experimentally for differences in the observed biological or chemical properties [26–28]. A
QSAR study usually leads to a predictive formula and attempts to model the activity of a
series of compounds using measured or computed properties of the compounds.
More recently, QSAR has been extended by including three-dimensional (3D) informa-
tion. In drug discovery, it is common to have measured activity data for a set of compounds
acting upon a particular protein, but not to have knowledge of the 3D structure of the active
site. In the absence of such 3D information, one may attempt to build a hypothetical model
of the active site that can provide insight on the nature of the latter. Three-dimensional
approaches such as HypoGen and/or HipHop are useful in building 3D pharmacophore mod-
els from the activity data and conformational structure [29]. They can be used as an alterna-
tive for QSAR methods because of their easy visualization and high prediction capability.
However, ranging activity values of a collection of conformational models of compounds
should be at least four orders of magnitude for the algorithm, HypoGen. The other algorithm
in 3D pharmacophore generation within Catalyst is called HipHop and is based on alignment
of common features present in highly potent compounds. The scalar affinity values of the
molecules are not regarded in this model generation mode.
HipHop pharmacophore models are derived by comparing a set of conformational models
and a number of 3D configurations of chemical features shared among the training set
molecules.
Molecular docking is a key tool in structural molecular biology and computer-assisted
drug design. The goal of ligand-protein docking is to predict the predominant binding model
(s) of a ligand with a protein of known 3D structure. In this study, we used fast flexible
docking to study the binding orientations and predict binding affinities of benzothiazole and
benzothiazolium derivatives. Such studies have been carried out to understand the forms of
interaction of 12 compounds, examined by Kaplan-Ozen and colleagues for human DNA to-
poisomerases [21]. The results obtained from this study will be useful in understanding the
inhibitory mode of benzothiazole and benzothiazolium derivatives, as well as in rapidly and
accurately predicting the activities of newly designed inhibitors on the basis of docking
scores. These models also provide some beneficial clues in structural modification for the
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design of new inhibitors for the treatment of cancer with much higher inhibitory activities
against DNA topoisomerase II.
2. Materials and methods
2.1 Molecular structures and optimization
A set of previously synthesized benzothiazole and 3-amino-benzothiazolium derivatives [16]
tested for DNA topoisomerase II inhibitory activity were chosen from our previous study [21]
Figure 1. (A) Conformational changes of topoisomerase II, after DNA binding [22]. (B) Docked posi-
tion of BM3: NH2 group at position 3 of benzothiazolium has H bond with Tyr782 (pink) and phenyl
ring on second position of benzothiazole ring has π–cation interactions with Lys720 (green). (C) Docked
position of M10: benzothiazole ring has π–cation interactions with Lys720 (green). (D) Docking overlay
of BM3 in atom charged surface area. (E) Docking overlay of M10 in atom charged surface area.
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as shown in Table 1. The DNA topoisomerase II inhibitory activities of these compounds are
represented as IC50 values in the millimolar, micromolar or nanomolar range [21]. The struc-
tures of all the compounds were constructed using the DS 3.5 Sketch Molecules module
(www.accelrys.com). The geometries of these compounds were subsequently optimized using
the Minimization module of DS 3.5 using the CHARMm (Chemistry at HARvard Macromo-
lecular Mechanics) force field. CHARMm provides a vast range of functionality for molecular




The most straightforward computational approaches for finding new leads for therapeutic
macromolecular targets are increasingly based on 3D information about proteins. Molecular
docking is an effective method to predict ligands, which are low molecular weight com-
pounds that may interact with a macromolecular target. A primary objective in molecular
docking is the ability to estimate the scoring function and evaluate protein–ligand interactions
as a means of hit identification (virtual screening) and lead optimization (to enhance desired
drug properties). This method is also successfully used as a computational tool to assist drug
discovery.
3.1.1 Preparation of the enzyme
The crystal structure of Saccharomyces cerevisiae topoisomerase II (PDB ID: 1BJT) was
retrieved from the Protein Data Bank (PDB) (www.rcsb.org) [31] and further modified for
docking calculations. For preparation of protein and ligands, DS 3.5 software was used. The
target protein was taken, hydrogens were added and their positions were optimized using the
all-atom CHARMm force field and the Adopted Basis set Newton Raphson (ABNR) method
available in the D.S 3.5 protocol until the root mean square deviation (RMSD) gradient was
<0.05 kcal/mol Å2. The minimized protein was defined as the receptor using the binding site
module. The binding site was defined from the cavity finding method, which was modified to
accommodate all the important interacting residues in the DNA binding site of topoisomerase
II enzyme. The binding sphere for 1BJT (6.12, 47.51, 26.54, 14.67) was selected from the
active site using the binding site tools.
3.1.2 Preparation of ligands
Previously synthesized benzothiazole and 3-amino-benzothiazolium derivatives were sketched;
all-atom CHARMm force field parameterization was assigned and then minimized using the
ABNR method as described above. Conformational search of the ligands was carried out
using a simulated annealing molecular dynamics (MD) approach. The ligands were heated to
a temperature of 700 K and then annealed to 200 K.
3.1.3 Docking
3.1.3.1 Core-constrained docking (CCD) subprotocol. The CCD subprotocol includes
conformer generation, core-constrained docking and scoring. In terms of core-constrained
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docking, use of the molecular docking algorithm CDOCKER is considered since it has been
shown to be a viable research tool [32,33]. CDOCKER is a CHARMm-based grid-enabled
docking method that uses soft core potentials and MD-generated random ligand conforma-
tions, and poses refinement in the active site using a simulated annealing process. In the origi-
nal work, CDOCKER treats the entire ligand as flexible during the initial docking phase. The
core-constrained docking method described here is a modification to the CDOCKER
CHARMm script that allows the scaffold to be locked but the rest of the ligand molecule to
be flexible during initial minimization and the MD conformer generation stage. The core is
allowed to move during final refinement with simulated annealing. Current docking tools do a
reasonable job at getting correct poses, but errors occur in a significant number of cases
[34,35]. Constraining the core to the crystal structure coordinates helps prevent incorrect
docking poses.
A grid is defined using the ‘Grid Extension’ parameter visible at the top level of the sub-
protocol and has been set to a default 8 Å distance from the ligand’s center of mass. Details
of the modified CDOCKER process begin with creation of the CHARMm set-up files and
generation of the CDOCKER protein grid. Ligand partial atomic charges and atom types
default to those of Momany–Rone force field [36] as implemented in CHARMm. The typed
ligand is first run through an ABNR minimization stage [30]. Ligand conformations are then
generated, in the absence of protein, through high-temperature MD simulations and a speci-
fied number (top level parameter, default = 20) of simulations are applied. The starting ligand
conformation for each MD simulation is that of its predecessor. Conformations resulting from
each MD simulation are then docked into the protein and minimized using steepest-descent
(SD), preparing them for final refinement. It is only during this initial docking and conformer
refinement phase where an energy grid for the ligand is imposed and nonbonded interactions
involving van der Waals and electrostatic potentials are softened, enabling enhanced sampling
of conformational space. The core is held fixed throughout the conformer generation and
docking phase. With the core now unconstrained, the docked poses are then further refined in
the receptor active site using a simulated annealing protocol and a full MD minimization (SD
+ conjugate-gradient). During this process the protein is held rigid. A user-specified number
of top poses (top level parameter), based on the largest minus CDOCKER scores, are saved
for the final rescoring step. Many of the advanced CHARMm parameters have been
optimized and do not require changing from their default values.
3.1.3.2 Calculated binding energy (CBE) subprotocol. The CDOCKER docked ligands are
rescored using a physics-based implicit solvation model as the final step. Within the CBE
subprotocol step, the docked ligand poses are rank scored in terms of their binding energies.
For this study, top CDOCKER poses of neutral and/or charged ligands were rescored using
Molecular Mechanics-Generalized Born with Molecular Volume (MM-GBMV) and/or Molec-
ular Mechanics-Generalized Born with Simple Switching (MM-GBSW) methods in DS
CHARMm, which approximates the binding energy [37–39]. Bound and unbound ligand
receptor energy terms contained within the calculated binding energy include three simula-
tions: free ligand; apo protein; and protein–ligand complex. Solute entropy contributions are
ignored in these calculations. Standard output includes the binding energy terms for the three
simulations and the net calculated binding energy as shown in Equation 1:
DDGBind ¼ DGCopmlex  DGLigand  GProtein (1)
In present study, the CDOCKER [33] method was performed using DS 3.5. All
docked poses were scored by applying the Analyze Ligand Poses subprotocol to analyze
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receptor–ligand interactions or a set of poses (the results of a docking run) using a vari-
ety of methods. Binding energies were also calculated by applying the Calculated Binding
Energy subprotocol in DS 3.5 using the in situ ligand minimization step in the ABNR
method. The lowest binding energy was taken as the best-docked conformation of the
compound for the macromolecule. The docking results were given in Table 2 and
Figure 1B–1E.
3.2 Pharmacophore modelling
According to the IUPAC definition, a pharmacophore model is ‘an ensemble of steric and
electronic features that is necessary to ensure the optimal intermolecular interactions with a
specific biological target and to trigger (or block) its biological response’. In DS software, a
pharmacophore is described as the essential features or chemical substructures and their
corresponding 3D locations that are responsible for the similar biological activities of a set of
compounds. Typically, pharmacophore features include hydrophobic, aromatic, hydrogen bond
acceptor, hydrogen bond donor, positive ionizable and negative ionizable.
3.2.1 Create pharmacophore automatically tools
The Create Pharmacophore Automatically tools allow you to automatically build pharmaco-
phore models from a ligand, a receptor or a receptor–ligand complex. The Auto Pharmaco-
phore Generation protocol is used based on a bioactive conformation. This protocol includes




(kcal/mol) Interacted residues (contact radius in 4 Å)*
M2 −37.996 Lys720 (2,37 Å)b, Arg781a, Tyr782e, Tyr784f
M6 −13.110 Lys720b, Gly765e, Ala766e, Arg781e, Tyr782c, Ile783e,
Tyr784e
M7 +27. 347 Lys720b, Gly765e, Ala766e, Ala778e, Arg781e, Tyr 782c,
Ile783e, Tyr784e
M9 −43.121 Lys720b, Arg781e, Tyr 782a, Tyr784f
M10 −25.198 Lys720b(2), Arg781f, Tyr 782f, Tyr784f
M15 −24.174 Lys720b,d, Arg781f, Tyr 782e, Ile783e, Tyr784f
BM6 +4.999 Lys720(2) (1,89-2,35 Å), Arg781f, Tyr782f, Tyr784f
BM1 −8.390 Lys720b, Arg781e, Tyr782 (2,06 Å), Tyr784e
BM7 −11.338 Lys720b, Asn764e, Gly765e, Ala766e, Arg781e, Tyr782f,
Ile783e, Tyr784f
BM2 +77.486 Lys720f, Arg781f, Tyr782a, Ile783f, Tyr784d (2,31 Å)
BM3 −26.257 Lys720b, Asn764f, Gly765f, Ala766f, Arg781e, Tyr782 (2,09
Å), Ile783e, Tyr784e






eVan der Waals interactions.
fElectrostatic interactions.
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all pharmacophore features, scores all possible pharmacophore combinations, and returns the
top pharmacophores. The score is based on a predictive model that uses simple descriptors
derived from the type and relative location of the pharmacophore features to predict the
number of hits from a diverse database.
The most widely used geometry- and feature-based pharmacophore elucidation method is
Catalyst from Accelrys, which is currently part of the DS package. Catalyst is an integrated
set of algorithms for conformation generation (ConFirm), molecular superimposition
(HipHop), pharmacophore generation (HypoGen) and database searching (Info). HipHop and
HypoGen provide two approaches for automatic pharmacophore generation.
HipHop provides feature-based alignment of a collection of compounds without consid-
ering the activity. It matches the chemical features of a molecule against drug candidate
molecules. HipHop takes a collection of conformational models of molecules and a selec-
tion of chemical features, and produces a series of molecular alignments in a variety of
standard file formats. HipHop begins by identifying configurations of features common to a
set of molecules. A configuration consists of a set of relative locations in 3D space and
associated feature types. A molecule matches the configurations if it possesses conforma-
tions and structural features that can be superimposed within a certain tolerance from the
corresponding ideal locations. HipHop also maps partial features of molecules in the align-
ment set. This provision gives the option to use partial mapping during the alignment. Par-
tial mapping allows us to identify larger, more diverse, more significant hypotheses and
alignment models without the risk of missing compounds that do not have to map to all of
the pharmacophore features.
In this study, pharmacophore analysis of the docking pose of BM3 was done by using
Auto Pharmacophore Generation method in DS 3.5. The Auto Pharmacophore Generation
protocol considers the following feature types to generate a selective pharmacophore model
Figure 2. (A) Pharmacophore model of the docking pose of BM3. The model contains four features:
one hydrophobic (cyan), two ring aromatic (orange) and one hydrogen bond donor (pink). (B) The
mapping of BM3 (fit value 3.96), to hypo10. (C) The mapping of BM7 (fit value 2.51), to hypo10.
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from a bioactive conformation of a single ligand (BM3): hydrogen bond acceptor; hydrogen
bond donor; hydrophobic feature; negative ionizable feature; positive ionizable feature; and
aromatic ring feature. Ten pharmacophore hypotheses were performed by using Auto Pharma-
cophore Generation. Hypothesis 10 (Hypo10) was chosen as the best hypothesis and tested to
the others. The distances of the best hypothesis were shown in Figure 2A. The fit values of
all the compounds were indicated in Table 3.
4. Results and discussion
In this study, we used benzothiazole derivatives and their corresponding benzothiazolium
forms that had been previously synthesized and shown inhibitory activities against DNA
topoisomerase II to interpret the interaction of the 12 molecules with DNA topoisomerase II
enzyme by theoretically comparing them with the experimental data.
In the earlier study, 3-amino-2-(2-bromobenzyl)-1,3-benzothiazole-3-ium 4-methylbenzene
sulfonate (BM3) was not only the most potent inhibitor, it was also extremely active com-
pared with the standard drug, etoposide, among the tested benzothiazoles and benzothiazoli-
ums [21]. In the present study, we showed the different activity mechanisms of
benzothiazoliums and benzothiazole derivatives by using Molecular Docking and Pharmaco-
phore identification protocols of DS 3.5.
It could be stated that BM3 is a catalytic inhibitor of topoisomerase II, and neither a poi-
son nor an intercalator. Moreover, that BM3 plays a preventive role in the DNA binding abil-
ity of topoisomerase II. This could be explained by BM3 directly interacts with the
topoisomerase II enzyme without interacting with DNA.
It was previously reported that there was a clear evidence for a covalent 5′ link between
DNA and the active site tyrosine (Tyr782) resident in topoisomerase II’s winged helix domain
(WHD) [22,23]. The docking studies showed that BM3 bound to Tyr782 at the active site to
prevent topoisomerase II enzyme binding to its substrate DNA. This was one of the reasons
why we selected the DNA topoisomerase II enzyme of S. cerevisiae, which was not bound to
DNA at its present form as its PDB code (1BJT) for the molecular docking studies. Benzothi-
azole and benzothiazolium derivatives were docked into the topoisomerase II enzyme (PDB
ID: 1BJT) using the CDOCKER method of DS 3.5. All the docking results are shown in
Table 2.








M10 No map found
M15 No map found
M2 No map found
M6 No map found
M7 No map found
M9 No map found
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Additionally, pharmacophore analysis of the docking pose of BM3 was performed using
the Auto Pharmacophore Generation method in DS 3.5. Hypothesis 10 was chosen as the best
hypothesis (Figure 2) and the rest of the compounds were used as a test set and mapped with
Hypo 10 using the rigid method in DS 3.5. All the fitted values were shown in Table 3.
As a result of the molecular modeling studies, the NH2 group attached to the third posi-
tion of the 3-amino-benzothiazolium ring in BM3, which is the most active compound, makes
a hydrogen bond with Tyr782 (binding energy is -26.257 kcal/mol). It also fitted to the hydro-
gen bond donor feature of Hypo10. The phenyl ring on the second position of the benzothia-
zole ring has π–cation interactions with Lys720 and fitted to the ring aromatic feature of
Hypo10 (Figure 1B, Figure 2B). In this way, BM3 binds to the active site tyrosine (Tyr782)
and shows inhibitory activity by blocking the active site of the enzyme, which seems consis-
tent with the experimental data found [21]. When we look at the compound M10, which is
the base form of BM3, the benzothiazole ring of this compound has only π–cation interac-
tions with Lys720 (Figure 1C) and it does not bind to Tyr782. Binding to Tyr782 is very
important such that BM3 prevents the binding of DNA, which binds via Tyr782, to DNA
topoisomerase II to continue its function to survive.
According to the pharmacophore analysis, it is observed that any of the benzothiazole
derivatives (M10, M15, M2, M6, M7 and M9) that have no cation form and do not carry
amino group at the third position are not mapped into Hypo 10 as seen in Table 3. Thus it
can be considered that the activity mechanisms of benzothiazoliums and benzothiazole
derivatives are different.
5. Conclusions
In 2013, some of the new six benzothiazole derivatives and their corresponding 3-amino-ben-
zothiazolium forms were synthesized and their inhibitory activities on DNA topoisomerase II
enzyme were determined by our group [21]. According to our earlier study, the 2-substituted-
benzothiazole derivatives (M2, M6, M7, M9, M10 and M15) indicated IC50 values of topoi-
somerase II inhibitory activity between 6.678 mM and 8.1 μM. Among the benzothiazole
derivatives, only 2-(4-bromophenyl)benzothiazole (M9) with an IC50 of 8.1 μM was found to
be more effective than the standard drug, etoposide (IC50 = 10 μM). However, 2-substituted-
3-aminobenzothiazolium derivatives (BM6, BM1, BM7, BM2, BM3 and BM4, which were
the 4-methylbenzene sulfonate salts of 3-amino-benzothiazolium derivatives of M2, M6, M7,
M9, M10 and M15, respectively) showed the inhibition effect on topoisomerase II with IC50
values of 8.457 mM to 39.4 nM. While the compound M10 had an IC50 value of 788 μM, its
3-amino-benzothiazolium p-toluenesulfonate salt (BM3) was found to be the most potent
inhibitor; it was also extremely active compared with the standard drug, etoposide, among the
tested compounds. The results suggested that BM3 inhibited topoisomerase II by a different
mechanism. To explore the mechanisms of the topoisomerase II inhibitory activity of benzo-
thiazole and 3-aminobenzothiazolium derivatives, molecular docking and pharmacophore
analysis were performed in this study.
It was previously reported that there was a clear evidence for a covalent 5’ link between
DNA and the active site tyrosine (Tyr782) resident in topoisomerase II’s winged helix domain
[22,23]. And, according to earlier studies, BM3 played a preventive role in the DNA binding
ability of topoisomerase II [21]. It could be considered that BM3 bound to this active site via
Tyr782 and played preventive role in DNA binding ability of topoisomerase II. We
showed the interactions of benzothiazole and 3-aminobenzothiazol-3-ium derivatives with
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topoisomerase II by using molecular docking studies. The results of this process were com-
pared with the experimental data to identify the interaction mechanisms of 12 compounds
with topoisomerase II. The most potent 3-amino-2-(2-bromobenzyl)-1,3-benzothiazole-3-ium
4-methylbenzene sulfonate (BM3) was chosen for the template revealing their interactions on
topoisomerase II.
From the results of molecular docking, it can be concluded that benzothiazolium com-
pounds bind to the active site tyrosine 782 to prevent the interactions between DNA and the
topoisomerase II enzyme. This property of the benzothiazoliums most probably executes the
cell proliferation process in tumor cells. The methods presented in this study are able to
provide valuable information about key features and interactions that are important for the
biological activity of the compound, BM3. Our present study showed that the 3-amino group,
as well as the CH2 bridge and the bromine atom bound on the ortho position of the phenyl
ring substituted at the second position of benzothiazole, play a significant role in enhancing
the activity. Moreover, according to the performed docking and pharmacophore analysis
results, it can be stated that 3-amino-benzothiazol-3-ium derivatives exhibit a totally different
mechanism than neutral benzothiazoles, which do not bind to the active site in the same way
as 3-amino-benzothiazolium compounds. In conclusion, BM3 would be a good anticancer
candidate for preclinical studies and 3-amino-benzothiazoliums are worth carrying onto
anticancer studies.
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